In vivo and in vitro response to octreotide LAR in a TSH-secreting adenoma: Characterization of somatostatin receptor expression and role of subtype 5

Pituitary

Volumn 14, Issue 2, 2011, Pages 141-147

  Gatto, Federico ^a   Barbieri, Federica ^a   Castelletti, Lara ^b   Arvigo, Marica ^a   Pattarozzi, Alessandra ^a   Annunziata, Francesca ^a   Saveanu, Alexandru ^c   Minuto, Francesco ^a   Castellan, Lucio ^b   Zona, Gianluigi ^b   Florio, Tullio ^a   Ferone, Diego ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c CNRS   (France)

Author keywords

Dopamine receptors; Octreotide; Pituitary tumors; Somatostatin receptors; TSH

Indexed keywords

CABERGOLINE; DOPAMINE 2 RECEPTOR; LIOTHYRONINE; OCTREOTIDE; SOMATOSTATIN RECEPTOR; SOMATOSTATIN RECEPTOR 1; SOMATOSTATIN RECEPTOR 2; SOMATOSTATIN RECEPTOR 5; TECHNETIUM 99M; THYROID HORMONE; THYROTROPIN; THYROXINE;

ADULT; ARTICLE; CASE REPORT; CELL CULTURE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; ECHOGRAPHY; HUMAN; HUMAN CELL; HYPERTHYROIDISM; IN VITRO STUDY; IN VIVO STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; THYROTROPIN RELEASE; THYROTROPIN SECRETING ADENOMA;

ADENOMA; ADULT; ANTINEOPLASTIC AGENTS, HORMONAL; CELLS, CULTURED; DELAYED-ACTION PREPARATIONS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; OCTREOTIDE; PITUITARY NEOPLASMS; RECEPTORS, SOMATOSTATIN; THYROTROPHS; THYROTROPIN;

EID: 79958159811     PISSN: 1386341X     EISSN: 15737403     Source Type: Journal    
DOI: 10.1007/s11102-010-0271-2     Document Type: Article

References (38)

1. Comi RJ, Gesundheit N, Murray L, Gorden P, Weintraub BD (1987) Response of thyrotropin-secreting pituitary adenomas to a long-acting somatostatin analogue. N Engl J Med 317:12-17 (Pubitemid 17093292)
2. Beck-Peccoz P, Brucker-Davis F, Persani L, Smallridge RC, Weintraub BD (1996) Thyrotropin-secreting pituitary tumors. Endocr Rev 17:610-638 (Pubitemid 26425259)
3. Ferone D, Gatto F, Arvigo M, Resmini E, Boschetti M, Teti C, Esposito D, Minuto F (2009) The clinical-molecular interface of somatostatin, dopamine and their receptors in pituitary pathophysiology. J Mol Endocrinol 42:361-370
4. Hofland LJ, van Koetsveld PM, Wouters N, Waaijers M, Reubi JC, Lamberts SW (1992) Dissociation of antiproliferative and antihormonal effects of the somatostatin analog octreotide on 7315b pituitary tumor cells. Endocrinology 131:571-577
5. Florio T, Thellung S, Corsaro A, Bocca L, Arena S, Pattarozzi A, Villa V, Massa A, Diana F, Schettini D, Barbieri F, Ravetti JL, Spaziante R, Giusti M, Schettini G (2003) Characterization of the intracellular mechanisms mediating somatostatin and lanreotide inhibition of DNA synthesis and growth hormone release from dispersed human GH-secreting pituitary adenoma cells in vitro. Clin Endocrinol (Oxf) 59:115-128 (Pubitemid 36774117)
6. Danila DC, Haidar JN, Zhang X, Katznelson L, Culler MD, Klibanski A (2001) Somatostatin receptor-specific analogs: effects on cell proliferation and growth hormone secretion in human somatotroph tumors. J Clin Endocrinol Metab 86:2976-2981 (Pubitemid 32673451)
7. Ren SG, Taylor J, Dong J, Yu R, Culler MD, Melmed S (2003) Functional association of somatostatin receptor subtypes 2 and 5 in inhibiting human growth hormone secretion. J Clin Endocrinol Metab 88:4239-4245 (Pubitemid 37153726)
8. Florio T, Thellung S, Arena S, Corsaro A, Spaziante R, Gussoni G, Acuto G, Giusti M, Giordano G, Schettini G (1999) Somatostatin and its analog lanreotide inhibit the proliferation of dispersed human non-functioning pituitary adenoma cells in vitro. Eur J Endocrinol 141:396-408 (Pubitemid 29529495)
9. Yoshihara A, Isozaki O, Hizuka N, Nozoe Y, Harada C, Ono M, Kawamata T, Kubo O, Hori T, Takano K (2007) Expression of type 5 somatostatin receptor in TSH-secreting pituitary adenomas: a possible marker for predicting long-term response to octreotide therapy. Endocr J 54:133-138 (Pubitemid 46481681)
10. Horiguchi K, Yamada M, Umezawa R, Satoh T, Hashimoto K, Tosaka M, Yamada S, Mori M (2007) Somatostatin receptor subtypes mRNA in TSH-secreting pituitary adenomas: a case showing a dramatic reduction in tumor size during short octreotide treatment. Endocr J 54:371-378 (Pubitemid 47105423)
11. Spada A, Bassetti M, Martino E, Giannattasio G, Beck-Peccoz P, Sartorio A, Vallar L, Baschieri L, Pinchera A, Faglia G (1985) In vitro studies on TSH secretion and adenylate cyclase activity in a human TSH-secreting pituitary adenoma. Effects of somatostatin and dopamine. J Endocrinol Invest 8:193-198
12. Wood DF, Johnston JM, Johnston DG (1991) Dopamine, the dopamine D2 receptor and pituitary tumours. Clin Endocrinol (Oxf) 35:455-466
13. Neto LV, Machado Ede O, Luque RM, Taboada GF, Marcondes JB, Chimelli LM, Quintella LP, Niemeyer P Jr, de Carvalho DP, Kineman RD, Gadelha MR (2009) Expression analysis of dopamine receptor subtypes in normal human pituitaries, nonfunctioning pituitary adenomas and somatotropinomas, and the association between dopamine and somatostatin receptors with clinical response to octreotide-LAR in acromegaly. J Clin Endocrinol Metab 94:1931-1937
14. Rocheville M, Lange DC, Kumar U, Patel SC, Patel RC, Patel YC (2000) Receptors for dopamine and somatostatin: formation of hetero-oligomers with enhanced functional activity. Science 288:154-157 (Pubitemid 30203051)
15. Grant M, Alturaihi H, Jaquet P, Collier B, Kumar U (2008) Cell growth inhibition and functioning of human somatostatin receptor type 2 are modulated by receptor heterodimerization. Mol Endocrinol 22:2278-2292
16. Barbieri F, Bajetto A, Stumm R, Pattarozzi A, Porcile C, Zona G, Dorcaratto A, Ravetti JL, Minuto F, Spaziante R, Schettini G, Ferone D, Florio T (2008) Overexpression of stromal cell-derived factor 1 and its receptor CXCR4 induces autocrine/paracrine cell proliferation in human pituitary adenomas. Clin Cancer Res 14:5022-5032
17. Florio T, Barbieri F, Spaziante R, Zona G, Hofland LJ, van Koetsveld PM, Feelders RA, Stalla GK, Theodoropoulou M, Culler MD, Dong J, Taylor JE, Moreau JP, Saveanu A, Gunz G, Dufour H, Jaquet P (2008) Efficacy of a dopamine-somatostatin chimeric molecule, BIM-23A760, in the control of cell growth from primary cultures of human non-functioning pituitary adenomas: a multi-center study. Endocr Relat Cancer 15:583-596 (Pubitemid 351880845)
18. Florio T, Pan MG, Newman B, Hershberger RE, Civelli O, Stork PJ (1992) Dopaminergic inhibition of DNA synthesis in pituitary tumor cells is associated with phosphotyrosine phosphatase activity. J Biol Chem 267:24169-24172
19. Chanson P, Weintraub BD, Harris AG (1993) Octreotide therapy for thyroid-stimulating hormone-secreting pituitary adenomas. A follow-up of 52 patients. Ann Intern Med 119:236-240 (Pubitemid 23327625)
20. Ohki M, Sato K, Tuchiya D, Sato S, Saito S, Kinjo T, Kayama T, Jokura H, Yoshimoto T (1999) A case of TSH-secreting pituitary adenoma associated with an unruptured aneurysm: successful treatment by two-stage operation and gamma knife. No To Shinkei 51:895-899
21. Macchia E, Gasperi M, Lombardi M, Morselli L, Pinchera A, Acerbi G, Rossi G, Martino E (2009) Clinical aspects and therapeutic outcome in thyrotropin-secreting pituitary adenomas: a single center experience. J Endocrinol Invest 32:773-779
22. Socin HV, Chanson P, Delemer B, Tabarin A, Rohmer V, Mockel J, Stevenaert A, Beckers A (2003) The changing spectrum of TSH-secreting pituitary adenomas: diagnosis and management in 43 patients. Eur J Endocrinol 148:433-442 (Pubitemid 36527414)
23. Mannavola D, Persani L, Vannucchi G, Zanardelli M, Fugazzola L, Verga U, Facchetti M, Beck-Peccoz P (2005) Different responses to chronic somatostatin analogues in patients with central hyperthyroidism. Clin Endocrinol (Oxf) 62:176-181 (Pubitemid 40203912)
24. Sharif N, Gendron L, Wowchuk J, Sarret P, Mazella J, Beaudet A, Stroh T (2007) Coexpression of somatostatin receptor subtype 5 affects internalization and trafficking of somatostatin receptor subtype 2. Endocrinology 148:2095-2105 (Pubitemid 46997042)
25. Filopanti M, Ballare E, Lania AG, Bondioni S, Verga U, Locatelli M, Zavanone LM, Losa M, Gelmini S, Peri A, Orlando C, Beck-Peccoz P, Spada A (2004) Loss of heterozygosity at the SS receptor type 5 locus in human GH- and TSH-secreting pituitary adenomas. J Endocrinol Invest 27:937-942 (Pubitemid 40124189)
26. Werner S (1979) Human pituitary adenomas with hypersecretion of TSH and prolactin. Evidence that receptor sites for dopamin may be absent on TSH producing while present on prolactin producing cells. Horm Metab Res 11:452-453
27. Bevan JS, Burke CW, Esiri MM, Adams CB, Ballabio M, Nissim M, Faglia G (1989) Studies of two thyrotrophin-secreting pituitary adenomas: evidence for dopamine receptor deficiency. Clin Endocrinol (Oxf) 31:59-70 (Pubitemid 19178145)
28. Shimatsu A, Murabe H, Nakamura Y, Mizuta H, Ihara C, Nakao K (1999) Long-term treatment with bromocriptine of a plurihormonal pituitary adenoma secreting thyrotropin, growth hormone and prolactin. Endocr J 46:159-165 (Pubitemid 29197761)
29. Wollesen F, Andersen T, Karle A (1982) Size reduction of extrasellar pituitary tumors during bromocriptine treatment. Ann Intern Med 96:281-286
30. Faglia G, Beck-Peccoz P, Piscitelli G, Medri G (1987) Inappropriate secretion of thyrotropin by the pituitary. Horm Res 26:79-99 (Pubitemid 17071701)
31. Scanlon MF, Howells S, Peters JR, Williams ED, Richards S, Hall R, Thomas JP (1985) Hyperprolactinaemia, amenorrhoea and galactorrhoea due to a pituitary thyrotroph adenoma. Clin Endocrinol (Oxf) 23:35-42 (Pubitemid 15042146)
32. Kienitz T, Quinkler M, Strasburger CJ, Ventz M (2007) Longterm management in five cases of TSH-secreting pituitary adenomas: a single center study and review of the literature. Eur J Endocrinol 157:39-46 (Pubitemid 47162564)
33. Colao A, Filippella M, Pivonello R, Di Somma C, Faggiano A, Lombardi G (2007) Combined therapy of somatostatin analogues and dopamine agonists in the treatment of pituitary tumours. Eur J Endocrinol 156(Suppl 1):S57-S63 (Pubitemid 46797845)
34. Baragli A, Alturaihi H, Watt HL, Abdallah A, Kumar U (2007) Heterooligomerization of human dopamine receptor 2 and somatostatin receptor 2 Co-immunoprecipitation and fluorescence resonance energy transfer analysis. Cell Signal 19:2304-2316 (Pubitemid 47361686)
35. Zatelli MC, Piccin D, Tagliati F, Bottoni A, Ambrosio MR, Margutti A, Scanarini M, Bondanelli M, Culler MD, degli Uberti EC (2005) Dopamine receptor subtype 2 and somatostatin receptor subtype 5 expression influences somatostatin analogs effects on human somatotroph pituitary adenomas in vitro. J Mol Endocrinol 35:333-341
36. Ferone D, de Herder WW, Pivonello R, Kros JM, van Koetsveld PM, de Jong T, Minuto F, Colao A, Lamberts SW, Hofland LJ (2008) Correlation of in vitro and in vivo somatotropic adenoma responsiveness to somatostatin analogs and dopamine agonists with immunohistochemical evaluation of somatostatin and dopamine receptors and electron microscopy. J Clin Endocrinol Metab 93:1412-1417 (Pubitemid 351522738)
37. Ferone D, Saveanu A, Culler MD, Arvigo M, Rebora A, Gatto F, Minuto F, Jaquet P (2007) Novel chimeric somatostatin analogs: facts and perspectives. Eur J Endocrinol 156(Suppl 1):S23-S28 (Pubitemid 46797840)
38. Saveanu A, Jaquet P (2009) Somatostatin-dopamine ligands in the treatment of pituitary adenomas. Rev Endocr Metab Disord 10:83-90